Table 4.
Cancers observed and expected, with standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs), according to duration of systemic lupus erythematosus (SLE)
| Total cancers | |||||
|---|---|---|---|---|---|
| SLE Duration (years) | Observed | Expected | SIR | 95%CI | |
| <1 | 59 | 26.9 | 2.20 | 1.67 | 2.83 |
| 1–4 | 148 | 117.4 | 1.26 | 1.07 | 1.48 |
| 5–10 | 151 | 141.8 | 1.06 | 0.90 | 1.25 |
| 10–19 | 189 | 179.9 | 1.05 | 0.91 | 1.21 |
| >20 | 97 | 97.8 | 0.99 | 0.80 | 1.21 |
| Hematological cancers | |||||
| SLE Duration (years) | Observed | Expected | SIR | 95%CI | |
| <1 | 10 | 1.7 | 5.82 | 2.79 | 10.70 |
| 1–4 | 32 | 7.5 | 4.24 | 2.90 | 5.99 |
| 5–10 | 21 | 9.2 | 2.27 | 1.41 | 3.48 |
| 10–19 | 36 | 11.7 | 3.09 | 2.16 | 4.28 |
| >20 | 12 | 6.4 | 1.88 | 0.97 | 3.29 |